Technical Analysis for APLT - Applied Therapeutics, Inc.

Grade Last Price % Change Price Change
grade C 9.42 4.78% 0.43
APLT closed up 4.78 percent on Monday, July 15, 2019, on 17 percent of normal volume.
0 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A N/A Up
See historical APLT trend table...

Date Alert Name Type % Chg
Inside Day Range Contraction 0.00%
Crossed Above 20 DMA Bullish 4.78%
Pocket Pivot Bullish Swing Setup 4.78%
Wide Range Bar Range Expansion 4.78%
Upper Bollinger Band Touch Strength 4.78%
Oversold Stochastic Weakness 4.78%
Oversold Stochastic Weakness 16.30%
Outside Day Range Expansion 16.30%
Oversold Stochastic Weakness 16.30%
Stochastic Buy Signal Bullish 12.54%

Older signals for APLT ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Read My Charts!
Configure default chart indicators
Basic chart:
Profile
Applied Therapeutics, Inc., a biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-001 that is in phase II clinical trials for treating diabetic cardiomyopathy, as well as is in phase I clinical trials to treat diabetic peripheral neuropathy. The company’s preclinical stage products include AT-001 for acute myocardial infraction; AT-007 for treating galactosemia; AT-003 to treat diabetic retinopathy; and AT-104 for the treatment of orphan hematological oncology. Applied Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York.
Biopharmaceutical Organ Systems Diabetes Cardiovascular Disease Diabetes Mellitus Diabetic Retinopathy Diabetic Peripheral Neuropathy Preclinical Stage Products Novel Products Peripheral Neuropathy Retinopathy
Is APLT a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 0 bearish and 5 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Jun 24 Applied Therapeutics Announces Initiation of Phase 1/2 Study of AT-007 in Galactosemia
Jun 21 Applied Therapeutics net loss widens in Q1
Jun 21 Applied Therapeutics reports Q1 results
Jun 21 Applied Therapeutics Reports First Quarter 2019 Financial Results
Jun 10 Applied Therapeutics Stock Jumps as Analysts Give It a Bullish Welcome
Jun 8 Stocks To Watch: Chewy IPO, Lululemon And Tesla On Tap
Jun 7 Applied Therapeutics to Present Data Highlighting AT-001 for the Treatment of Diabetic Cardiomyopathy in Late Breaking Session at the American Diabetes Association 79th Annual Scientific Sessions
Jun 1 The Week Ahead In Biotech: ASCO Presentations Pick Up The Pace
May 28 Applied Therapeutics' AT-007 an orphan drug for Galactosemia
May 28 Applied Therapeutics Announces FDA Orphan Drug Designation for AT-007 in Galactosemia
See more APLT news...
Indicators
Indicator Value
52 Week High 11.2
52 Week Low 7.95
Average Volume 41,663
200-Day Moving Average 0.0
50-Day Moving Average 0.0
20-Day Moving Average 8.5613
10-Day Moving Average 8.426
Average True Range 0.5827
ADX 19.1
+DI 24.1604
-DI 14.4139
Chandelier Exit (Long, 3 ATRs ) 8.3918
Chandelier Exit (Short, 3 ATRs ) 9.8081
Upper Bollinger Band 9.4301
Lower Bollinger Band 7.6925
Percent B (%b) 0.99
BandWidth 20.295983
MACD Line -0.2196
MACD Signal Line -0.3581
MACD Histogram 0.1385
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 10.38
Resistance 3 (R3) 10.27 9.85 10.22
Resistance 2 (R2) 9.85 9.60 9.90 10.17
Resistance 1 (R1) 9.63 9.45 9.74 9.74 10.11
Pivot Point 9.21 9.21 9.26 9.26 9.21
Support 1 (S1) 8.99 8.96 9.10 9.10 8.73
Support 2 (S2) 8.57 8.81 8.62 8.67
Support 3 (S3) 8.35 8.57 8.62
Support 4 (S4) 8.46